Gil Ben-Menachem, Steven M Ferguson, Krishna Balakrishnan
{"title":"Beyond Patents and Royalties: Perception and Reality of Doing Business with the NIH.","authors":"Gil Ben-Menachem, Steven M Ferguson, Krishna Balakrishnan","doi":"10.1038/bioent895","DOIUrl":null,"url":null,"abstract":"<p><p>Young, and mid size biotech companies can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.</p>","PeriodicalId":83088,"journal":{"name":"The journal of biolaw & business","volume":"24 1","pages":"17-20"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/bioent895","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journal of biolaw & business","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/bioent895","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
Young, and mid size biotech companies can benefit hugely from the US National Institutes of Health (NIH), not least because of the agency's non-dilutive funding, guidance, and opportunities for collaboration. Increasingly, however, there is a fair bit of misunderstanding about what the NIH can and cannot do for a biotech entrepreneur.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
